A beta-glucan purified from a mutant Saccharomyces cerevisiae strain was tested in several mouse tumor and metastasis models. Preventive or therapeutic administration reduced reported tumor burden or metastasis and sometimes prolonged survival, while the glucan did not directly inhibit colon cancer cells in vitro. Splenocyte proliferation, macrophage cytokines, and tumoricidal activity increased, supporting an immune-mediated explanation. These are preclinical yeast-glucan results and do not demonstrate cancer treatment efficacy in patients or equivalence with Aureobasidium glucan.
Mutant-yeast beta-glucan was tested in multiple mouse tumor models and immune assays.
Metastasis and tumor growth decreased in some models alongside immune-cell activation.
Mouse yeast-glucan findings do not prove patient benefit or Aureobasidium equivalence.
AI-generated summary for accessibility. Always refer to the original paper.
Yoon T., Kim T., Lee H., Shin K., Yun Y., Won C., Song S., Kim S.. Anti-tumor metastatic activity of β-glucan purified from mutated Saccharomyces cerevisiae. International Immunopharmacology. 2008. DOI: 10.1016/j.intimp.2007.10.005.
For scientific reference only. Not medical advice. Consult a qualified healthcare professional. See our Medical Disclaimer.